Become A Featured Company

Cannabis Technologies Looks to Diversify Pipeline with New Hire

Ryan Allway

September 18th, 2014

News, Top Story

[stockchart symbol=CANLF]

Cannabis Technologies Inc. [stockquote symbol=CANLF] (TSX-V: CAN), a biopharmaceutical drug discovery and development company focused on the pharmacology and therapeutic potential of cannabinoids (CBDs), recently announced the appointment of Peter Huang as its Senior Bioinformatician. The move could unlock shareholder value by broadening its pipeline over the coming years.

With more than 17 years of experience as a bioinformatician, software developer, and biological researcher, Mr. Huang recently worked with the Vineland Research and Innovation Center as a Senior Bioinformatician and with U.S. Genomics as a Bioinformatics Scientist. He received a Master of Science in Botany and Microbiology from Auburn University and a BS in Computer Science from Simon Fraser University.

Mr. Huang’s efforts at Cannabis Technologies will be focused on discovering novel cannabis-based drug therapies to add to its growing pipeline. By expanding the pipeline, shareholders benefit from both diversified risk and upside potential as therapies move closer to commercialization. These dynamics could help accelerate the company’s growth over the coming years.

In addition to creating value, building its clinical pipeline could increase the likelihood of a merger or acquisition in the future. Many large pharmaceutical companies are struggling with expiring patents on major blockbuster drugs (the so-called patent cliff), a trend that has already accelerated some mergers and acquisitions in the space. Cannabis could become a viable target if proven successful in treating serious medical conditions.

Growing Pipeline Driven by Platform Technology

Cannabis Technologies developed its proprietary Cannabinoid Drug Design Platform as a bioinformatics tool designed to identify individual chemical compounds from the cannabis plant that can be targeted to develop therapies for specific diseases and conditions. Mr. Huang will leverage the platform to accelerate the discovery of new therapies based on proven genomics and metabolomics.

There are many companies developing cannabis therapies, including names like Cannabis Science Inc. [stockquote symbol=CBIS] and INSYS Therapeutics Inc.’s [stockquote symbol=INSY]. Insys recently received an orphan drug designation from the FDA for its CBD-based brain cancer treatment. Cannabis Technologies differentiates itself with a platform technology capable of rapidly growing its clinical pipeline beyond just a handful of clinical trials that could make or break a company. So far, the platform has helped the company add CTI-085 for Glaucoma and CTI-091 for Arthritis to its stable of developmental drugs, and the company plans to add drugs to address other disease conditions.

CTI-085 is a topical formation containing a proprietary compound of cannabinoids and non-cannabis-based active ingredients for the treatment of glaucoma. After about a year of discovery and preclinical studies, the compound has shown efficacy in lowering intraocular pressure in animal models. The therapy’s goal is to be a safer alternative without the systemic side effects of other drugs.

CTI-091 is a proprietary mix of cannabinoids and non-cannabis-based active ingredients designed to relieve joint pain and swelling associated with arthritis and joint disease. Preliminary studies showed that the compound suppresses the human macrophage interleukin-6 – a major biomarker for inflammation. The team is currently working on a new delivery system to enhance retention and absorption.

Looking Ahead

Cannabis Technologies trades with a market capitalization of less than $10 million with two preclinical compounds in its pipeline. With the hiring of Mr. Huang, the company could expand its pipeline in the near-term to create additional opportunities and diversify risk for shareholders. These dynamics alone should help improve its valuation, assuming everything else remains equal.

Investors may want to keep an eye on the stock over the coming months as management works to expand the pipeline and progress its existing clinical trials. With these near-term catalysts in place, the company could see its valuation expand and its visibility within the marketplace increase over time.

For more information about the company, see the following resources:

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading